(1)
Regulatory News:
THERACLION (Paris:ALTHE) (ISIN: FR0010120402; Mnemo: ALTHE, PEA-PME eligible), an innovative company specializing in the development of medical equipment for echotherapy treatment, notably for varicose veins, today announces its sales revenues for the year 2020 and roll-out strategy for 2021.
Roll-out strategy 2021
SONOVEIN S, the last generation of SONOVEIN systems (CE marking obtained in Oct. 2020), makes SONOVEIN a strong alternative in treatment of varicose veins. It allows faster non-surgical treatment on an ambulatory basis without the need for anaestesia. Since October the company has made significant progress with their roll-out strategy. For 2021, it plans to further expand business development in new territories including Asia. Theraclion will also significantly increase SONOVEIN S installations at new key opinion leader sites. These international experts show strong interest in this distruptive technology. Once equipped, their centers of excellen